-+ 0.00%
-+ 0.00%
-+ 0.00%

RBC Capital Reiterates Outperform on BioCryst Pharma, Maintains $11 Price Target

Benzinga·04/11/2025 15:19:19
Listen to the news
RBC Capital analyst Brian Abrahams reiterates BioCryst Pharma (NASDAQ:BCRX) with a Outperform and maintains $11 price target.